Pfizer has acquired 50% stake in IGNITE Immunotherapy. Pursuant to the acquisition, Pfizer will hold 50% equity investment in IGNITE and be responsible for providing research and development funding for three years.
Go deeper with GlobalData
The acquisition will allow Pfizer to develop a new research programme to discover novel vaccinia viruses and also to expand its presence in the immuno-oncology field.
KDB Capital has acquired 6.7% stake in Anygen.
The acquirer is a financial services provider company, while the target is a peptide synthesis provider.
See Also:
Image: Pfizer has acquired 50% stake in IGNITE Immunotherapy.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Thank you!
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalData
